Chemotherapy for ovarian cancer in Republic of Korea: Our Best Clinics and Costs 2026

The standard chemotherapy regimen for ovarian cancer in South Korea follows the Korean Society of Gynecologic Oncology (KSGO) guidelines. Patients typically receive the TC protocol, combining Paclitaxel and Carboplatin intravenously. This foundational treatment usually consists of 6 cycles administered every 3 weeks at JCI-accredited centers in Seoul.

• First-line therapy: Standard intravenous Carboplatin and Paclitaxel administered over 6 cycles.
• Maintenance protocols: Bevacizumab or PARP inhibitors like Olaparib for BRCA-mutated cases.
• Advanced techniques: HIPEC (Hyperthermic Intraperitoneal Chemotherapy) is frequently used during debulking surgery.
• Recurrence management: Secondary options include Pegylated Liposomal Doxorubicin (PLD) or Topotecan for resistance.

Bookimed Expert Insight: South Korean oncology centers like Severance Hospital and Asan Medical Center prioritize patient safety through complete digitalization. SNUBH uses the BESTcare system to eliminate medication errors during complex chemotherapy dosing. This high-tech infrastructure supports extremely precise AUC 5-6 Carboplatin dosing and aggressive anti-emetic protocols, which significantly improves the patient experience during treatment.

Patient Consensus: Patients emphasize the importance of CA-125 tracking for monitoring response. Most recommend arranging a translator early to ensure clear communication about managing side effects during routine inpatient stays.

Ovarian cancer chemotherapy in South Korea is required for almost all stage II to IV patients and stage I cases with high-risk factors. Korean Society of Gynecologic Oncology guidelines mandate treatment for high-grade tumors, clear cell histology, or tumor rupture during surgery to prevent recurrence.

• Advanced stages: Standard for all stage II, III, and IV epithelial ovarian cancer patients.
• High-risk stage I: Required for grade 3 tumors or specific clear cell carcinoma histology.
• Neoadjuvant approach: Administered before surgery if tumors are too extensive for initial optimal debulking.
• Recurrence protocol: Recommended for returning cancer, often combined with bevacizumab or PARP inhibitors.

Bookimed Expert Insight: Top-tier Seoul centers like Asan Medical Center and Severance Hospital prioritize early genetic testing. Data shows identifying BRCA or HRD mutations immediately helps patients qualify for targeted therapies. This approach often integrates with standard carboplatin and paclitaxel regimens for better outcomes.

Patient Consensus: Many patients noted that doctors may recommend starting chemotherapy quickly after diagnosis. They suggest preparing anti-nausea medications early as side effects can feel more intense than expected.

HIPEC is available at specialized South Korean cancer centers and is recommended for advanced stage III ovarian cancer patients who respond well to neoadjuvant chemotherapy. This intensive procedure combines surgical debulking with heated intraperitoneal chemotherapy to target microscopic cancer cells directly within the abdominal cavity.

• Specialized facilities: Asan Medical Center and Severance Hospital provide advanced multidisciplinary oncology care.
• Accreditation standards: Top Seoul clinics maintain Joint Commission International (JCI) and KOIHA quality certifications.
• Strategic recommendation: Medical boards suggest HIPEC for peritoneal-limited recurrences rather than frontline treatment.
• Recovery period: Patients typically require up to 3 months for full recovery after surgery.

Bookimed Expert Insight: South Korea offers a significant technological edge for HIPEC as leading facilities like Seoul National University Hospital are fully digitalized. This integration reduces medical errors during complex, multi-hour surgeries. While chemotherapy in Korea costs $2,800 to $8,500, patients save about _price_percent_discount_% compared to US prices of _price_compare_US_average_.

Patient Consensus: Survivors describe HIPEC as a game-changer for eliminating micro-metastases despite severe post-operative pain. Many report staying cancer-free for over 3 years after receiving this treatment alongside cytoreductive surgery.

Targeted therapies like PARP inhibitors and Bevacizumab are standard maintenance treatments for ovarian cancer in the Republic of Korea. Top facilities like Asan Medical Center and Severance Hospital integrate Olaparib (Lynparza), Niraparib (Zejula), and Bevacizumab (Avastin) into protocols for BRCA-mutated or high-risk cases.

• Available PARP inhibitors: Olaparib and Niraparib are approved first-line maintenance therapies for advanced stages.
• Bevacizumab usage: Typically administered for 12–22 cycles alongside platinum-based chemotherapy to delay progression.
• Regulatory standards: Facilities like Ewha Womans University Medical Center maintain JCI-accreditation for oncology.
• Diagnostic routine: BRCA and HRD genetic testing are standard procedures to determine medication eligibility.

Bookimed Expert Insight: While chemotherapy in Korea starts at $2,800, choosing a digitalized center like Seoul National University Bundang Hospital or SNUH can reduce medication errors. These centers use advanced electronic systems to manage complex dosing for combination therapies like Bevacizumab plus Olaparib, which are frequently used for HRD-positive patients.

Patient Consensus: Patients report that genetic testing is exceptionally fast in Seoul, allowing quick access to targeted drugs. While results are highly effective, many emphasize the need for close monitoring of side effects like fatigue or hypertension.

Top hospitals for ovarian cancer chemotherapy in Korea include Samsung Medical Center, Asan Medical Center, and Seoul National University Hospital. These JCI-accredited facilities rank among the world's top 10 for oncology. They provide advanced treatments like HIPEC, targeted therapies, and personalized genomic dosing.

• Samsung Medical Center: Ranked 3rd globally, offering advanced HIPEC and English-speaking coordinators.
• Asan Medical Center: Korea's largest hospital treating 2,500+ inpatients daily with aggressive trial regimens.
• Seoul National University: Features the highest cancer treatment statistics and research-driven genomic protocols.
• Severance Hospital: Specializes in outpatient chemotherapy and fertility-sparing neoadjuvant treatments for younger patients.
• Ewha Womans University: Focuses on gynecological oncology and aesthetic outcomes with minimally invasive techniques.

Bookimed Expert Insight: The Big 5 hospitals in Seoul manage massive patient volumes, with Asan Medical Center alone performing over 65,000 operations annually. This high repetition leads to refined chemotherapy protocols that often include clinical trials. These trials can reduce treatment costs by 50% while providing closer monitoring.

Patient Consensus: Patients value the aggressive treatment regimens and superior side effect management compared to Western facilities. Many recommend using KakaoTalk for direct surgeon communication and second opinions before traveling.